Hasil Pencarian  ::  Simpan CSV :: Kembali

"[ABSTRAKLatar Belakang : Pada penderita Systemic Lupus Erythematosus (SLE) terdapat defek pada sel T regulator baik dalam hal jumlah maupun fungsi sel T regulator. Pemberian probiotik dalam hal ini pemberian Lactabacillus reuteri diharapkan mampu menstimulasi timbulnya respon imun yang bersifat imunoregulator dengan cara meningkatkan jumlah sel T regulator dan menurunkan produksi IL6. Tujuan : Mengetahui pengaruh pemberian probiotik terhadap toleransi sistem imun penderita SLE melalui perubahan kadar T regulator (CD4+CD25+Foxp3+) dan IL 6. Metode :30 subjek pasien SLE dengan manifestasi ringan yang datang ke poliklinik Alergi Imunologi RSCM, diberikan probiotik Lactobacillus reuteri (15 orang) dan placebo (15 orang) selama 8 minggu. CD4+CD25+FoxP3+ dan IL 6 diperiksa sebelum dan sesudah perlakuan menggunakan flowcytometri dan pemeriksaan ELISA. Hasil : Pemberian Lactobacillus reuteri selama 8 minggu meningkatkan kadarCD4+CD25+FoxP3+secara bermakna (1,38+ 8,36% VS 3,71+3,17% ; P=0,007 ; CI =-3,91 ? -0,74) . Terdapat penurunan kadar IL 6 setelah perlakuan, baik pada kelompok yang diberikan Lactobacillus reuteri (4,76+5,75 pg/ml VS 3,7 +3,36 pg/ml ; P=0,25 ; CI -0,83- 2,9) maupun pada kelompok placebo ( 2,6+2,02 pg/ml VS 2,07+2,39 ; P= 0,35 ; CI = -0,57 ? 1,52). Namun begitu, pada akhir penelitian perubahan tersebut tidak menimbulkan perbedaan bermakna kadar CD4+CD25+FoxP3+dan IL 6antara kedua kelompok. Kesimpulan :Terjadi peningkatan bermakna kadar CD4+CD25+FoxP3+ pada kelompok yang diberikan probiotik Lactobacillus reuteri selama 8 minggu.

---

ABSTRACTBackgroud : In patients with Systemic Lupus Erythematosus (SLE) there areabnormality on T lymphocytes, including the existence of a defect in the regulatory Tcells both in terms of number and function. Giving probiotic, in this caseLactabacillus reuteri administration, is expected to stimulate the immune response tobe more tolerance by increasing the number of regulatory T cells and decreasing theIL6 production.Aim : To know the effect of probiotic (Lactobacillus reuteri ) on the immune systemof patients with SLE through changes in the levels of regulatory T cells (CD4+CD25+Foxp3+) and IL 6Method :Thirty ofSLE patients with mild manifestations, who came to Allergy andImmunology Clinic of Cipto Mangunkusumo Hospital, were given the probioticLactobacillus reuteri (15 people) and placebo (15 people) for 8 weeks. CD4+ CD25 +FoxP3+ and IL 6 were examined before and after exposure using flowcytometri andELISA. We then analyzed the levels of CD4 + CD25 + FoxP3 + and IL6 before andafter exposure.Result : Administration of Lactobacillus reuteri for 8 weeks brought statisticallysignificant improvement on CD4+ CD25 + FoxP3 +level (1,38+ 8.36% + 3.17% vs.3.71; P = 0.007; CI = -3.91 - -0.74). There were decreased level of IL 6 inLactobacillus reuteri group (4.76 + 5.75 pg / ml VS3,71 + 3.36 pg / ml; P = 0.25; CI -0,83- 2, 9) and the placebo group (2.6 + 2.02 pg / ml vs. 2.07 + 2.39; P = 0.35; CI = -0.57 - 1.5). However,at the end of study, those changes didn?t make statisticallysignificant difference of CD4+CD25+FoxP3+ and IL 6 level between two group.Conclusion : A significant increase of the levels of CD4 + CD25 + FoxP3 + were foundafter 8 weeks Lactobacillus reuteri administration, Backgroud : In patients with Systemic Lupus Erythematosus (SLE) there areabnormality on T lymphocytes, including the existence of a defect in the regulatory Tcells both in terms of number and function. Giving probiotic, in this caseLactabacillus reuteri administration, is expected to stimulate the immune response tobe more tolerance by increasing the number of regulatory T cells and decreasing theIL6 production.Aim : To know the effect of probiotic (Lactobacillus reuteri ) on the immune systemof patients with SLE through changes in the levels of regulatory T cells (CD4+CD25+Foxp3+) and IL 6Method :Thirty ofSLE patients with mild manifestations, who came to Allergy andImmunology Clinic of Cipto Mangunkusumo Hospital, were given the probioticLactobacillus reuteri (15 people) and placebo (15 people) for 8 weeks. CD4+ CD25 +FoxP3+ and IL 6 were examined before and after exposure using flowcytometri andELISA. We then analyzed the levels of CD4 + CD25 + FoxP3 + and IL6 before andafter exposure.Result : Administration of Lactobacillus reuteri for 8 weeks brought statisticallysignificant improvement on CD4+ CD25 + FoxP3 +level (1,38+ 8.36% + 3.17% vs.3.71; P = 0.007; CI = -3.91 - -0.74). There were decreased level of IL 6 inLactobacillus reuteri group (4.76 + 5.75 pg / ml VS3,71 + 3.36 pg / ml; P = 0.25; CI -0,83- 2, 9) and the placebo group (2.6 + 2.02 pg / ml vs. 2.07 + 2.39; P = 0.35; CI = -0.57 - 1.5). However,at the end of study, those changes didn’t make statisticallysignificant difference of CD4+CD25+FoxP3+ and IL 6 level between two group.Conclusion : A significant increase of the levels of CD4 + CD25 + FoxP3 + were foundafter 8 weeks Lactobacillus reuteri administration]"

"Latar belakang: Enterokolitis nekrotikans EKN merupakan inflamasi pada saluran cerna yang sering terjadi pada bayi prematur. Lactobacillus reuteri merupakan mikroorganisme hidup yang dilaporkan dapat mencegah kejadian EKN, intoleransi minum dan menurunkan angka mortalitas. Tujuan: Mengidentifikasi kejadian EKN pada bayi prematur yang mendapat Lactobacillus reuteri DSM 17938 dan sekunder kejadian sepsis, intoleransi minum, waktu mencapai full feeding, lama hari perawatan, efek samping dan kematian. Metode: Uji klinis acak tersamar ganda membandingkan pemberian Lactobacillus reuteri dengan plasebo pada neonatus usia gestasi 28-34 minggu dan berat lahir 1000-1800 gram di Rumah Sakit Dr. Cipto Mangunkusumo. Masing-masing kelompok terdiri dari 47 subjek. Hasil: Kejadian EKN stadium 2 dan 3 didapatkan 3 subjek 6,4 pada kelompok plasebo dan tidak ada ada pada kelompok probiotik RR 1,07 IK 95 0,99-1,15, p=0,24 . Intoleransi minum berupa muntah, kembung, atau keduanya lebih rendah pada kelompok probiotik dibandingkan plasebo 8,5 vs. 25,5 , RR 0,33 IK 95 0,12-0,96, p=0,03 . Proven sepsis pada kelompok probiotik dan plasebo tidak berbeda bermakna 2,1 vs. 6,4 , p=0,62 . Waktu mencapai full feeding dan lama perawatan tidak didapatkan perbedaan bermakna antara kedua kelompok. Efek samping yang diobservasi berupa diare tidak berbeda bermakna antara kedua kelompok 2,1 vs. 4,3 , p=1,00 . Kematian tidak berbeda bermakna antara kedua kelompok 2,1 vs. 8,5 , p=0,36. Simpulan: Kejadian EKN terjadi pada kelompok plasebo sebesar 6,4 dan tidak ada pada kelompok probiotik. Intoleransi minum secara bermakna lebih rendah pada kelompok probiotik dibandingkan plasebo. Luaran sekunder proven sepsis, waktu mencapai full feeding, lama perawatan, efek samping diare dan kematian tidak didapatkan perbedaan bermakna antara kedua kelompok.

---

Background: Necrotizing enterocolitis NEC is an inflammatory disorder of the gastrointestinal tract that often occurs in preterm infants. Lactobacillus reuteri is a living microorganism that has been reported to prevent NEC.

Objectives: Identify the NEC prevalence in preterm infants receiving Lactobacillus reuteri DSM 17938 with secondary outcomes including sepsis, feeding intolerance, time to reach full feeding, length of stay, adverse effects, and mortality.

Methods: Double blind randomized controlled trial of Lactobacillus reuteri DSM 17938 versus placebo in 28 34 weeks of gestational neonates and birth weight 1000 1800 grams at Dr. Cipto Mangunkusumo Hospital. Each group consisted of 47 subjects.

Results The prevalence of NEC stages 2 and 3 were found in three subjects 6,4 of the placebo whereas none occurred in the probiotic RR 1.07, 95 CI 0.99 1.15, p 0.24 . Feeding intolerance vomiting, distension, or both were found to be lower in the probiotic compared to the placebo 8.5 vs 25.5 RR 0.33 95 CI 0.12 0.96, p 0.03. No significant differences were found between both groups for the proven sepsis, time to reach full feeding, length of stay, and adverse effects of diarrhea. Mortality rates were 2.1 in the probiotic and 8.5 in the placebo, p 0.36.

Conclusion 6,4 of the placebo group experienced NEC whereas none occurred in the probiotic group. Feeding intolerance was found to be significantly lower in the group receiving probiotics compared to the placebo group. Secondary outcomes including proven sepsis, time to reach full feeding, length of stay, adverse effect diarrhea , and mortality were also not found to be significantly different between both trial groups."

"ABSTRAKLatar belakang: Konstipasi fungsional kronik adalah masalah yang seringditemukan di masyarakat dengan prevalensi sekitar 15-25%. Konstipasimenimbulkan berbagai gejala, meningkatkan angka kesakitan dan biaya kesehatan.Saat ini, penggunaan probiotik untuk pengobatan konstipasi kronik pada dewasatelah diteliti, namun, dari berbagai penelitian yang telah dilakukan hasil yangdiperoleh masih terbatas dan menimbulkan kontroversi.Tujuan: Untuk menilai manfaat Lactobacillus reuteri dalam memperbaiki skorkonstipasi Agachan, jumlah L. reuteri feses dan pH feses pada pasien konstipasifungsional kronik.Metode: Uji acak tersamar ganda dilakukan pada 40 pasien dewasa (12 laki-laki/28 perempuan), rerata usia 45,95+/-16 tahun, yang menderita konstipasi fungsionalkronik sesuai kriteria Rome III, selanjutnya dilakukan randomisasi dan diberikanL.reuteri atau Plasebo selama 4 minggu.Hasil: Pada minggu ke-4, setelah pemberian L.reuteri terjadi perbaikan gejalakonstipasi, yang dinilai dari penurunan skor konstipasi Agachan dari 17 menjadi 8dengan p <0.001. Terjadi peningkatan jumlah L.reuteri feses dari 6,80x10 menjadi 2,12x10 8 dengan p <0,001 dan penurunan pH feses dari 5,44 (SB 0,70) menjadi4,78 (SB 0,56) dengan p <0,001 pada kelompok L.reuteri, sedangkan padakelompok Plasebo tidak didapatkan hasil yang bermakna pada perbaikan skorkonstipasi Agachan, jumlah L.reuteri feses dan pH feses.Kesimpulan: L.reuteri lebih efektif dibandingkan Plasebo dalam memperbaikikonstipasi, meningkatkan jumlah L.reuteri feses dan menurunkan pH feses padapasien konstipasi fungsional kronik dewasa.

---

ABSTRACTBackground: Chronic functional constipation is a common problem that affectsbetween 15-25% of the population and cause symptoms and disorders, that createsdiscomfort, morbidity and high costs for health care. Recently, the consumption ofprobiotics in treating chronic constipation in adults have been investigated.However, there are still limited and controversial evidences available fromcontrolled trials.Aim: To evaluate the effects of L. reuteri in improving the Agachan constipationscore, the number of L. reuteri in the feces and the fecal pH in the patients withchronic functional constipation.Methods: A double-blind, placebo RCT was conducted in 40 adult (12 male/ 28female with mean age 45,95+/-16 years) affected by chronic functional constipationaccording to Rome III criteria. Patients were randomly assigned to receive asupplementation of L.reuteri or Placebo for 4 weeks.Results: At week 4, the decrease in Agachan constipation score was from 17.00 to8.00 with p <0.001, the increase number of L.reuteri was from 6,80x10with p <0,001 and the decrease of pH feces was from 5,44 (SB 0,70) to 4,78 (SB0,56) with p <0,001 in the L. reuteri group, otherwise in the Placebo group therewere no significant results in Agachan constipation score, the number of L.reuteriand fecal pH assessed.Conclusion: L.reuteri is more effective than the Placebo group in improving theAgachan constipation score, increasing the number of L. reuteri in the feces anddecreasing the fecal pH in adult with chronic functional constipation.;Background: Chronic functional constipation is a common problem that affectsbetween 15-25% of the population and cause symptoms and disorders, that createsdiscomfort, morbidity and high costs for health care. Recently, the consumption ofprobiotics in treating chronic constipation in adults have been investigated.However, there are still limited and controversial evidences available fromcontrolled trials.Aim: To evaluate the effects of L. reuteri in improving the Agachan constipationscore, the number of L. reuteri in the feces and the fecal pH in the patients withchronic functional constipation.Methods: A double-blind, placebo RCT was conducted in 40 adult (12 male/ 28female with mean age 45,95+/-16 years) affected by chronic functional constipationaccording to Rome III criteria. Patients were randomly assigned to receive asupplementation of L.reuteri or Placebo for 4 weeks.Results: At week 4, the decrease in Agachan constipation score was from 17.00 to8.00 with p <0.001, the increase number of L.reuteri was from 6,80x10with p <0,001 and the decrease of pH feces was from 5,44 (SB 0,70) to 4,78 (SB0,56) with p <0,001 in the L. reuteri group, otherwise in the Placebo group therewere no significant results in Agachan constipation score, the number of L.reuteriand fecal pH assessed.Conclusion: L.reuteri is more effective than the Placebo group in improving theAgachan constipation score, increasing the number of L. reuteri in the feces anddecreasing the fecal pH in adult with chronic functional constipation.;Background: Chronic functional constipation is a common problem that affectsbetween 15-25% of the population and cause symptoms and disorders, that createsdiscomfort, morbidity and high costs for health care. Recently, the consumption ofprobiotics in treating chronic constipation in adults have been investigated.However, there are still limited and controversial evidences available fromcontrolled trials.Aim: To evaluate the effects of L. reuteri in improving the Agachan constipationscore, the number of L. reuteri in the feces and the fecal pH in the patients withchronic functional constipation.Methods: A double-blind, placebo RCT was conducted in 40 adult (12 male/ 28female with mean age 45,95+/-16 years) affected by chronic functional constipationaccording to Rome III criteria. Patients were randomly assigned to receive asupplementation of L.reuteri or Placebo for 4 weeks.Results: At week 4, the decrease in Agachan constipation score was from 17.00 to8.00 with p <0.001, the increase number of L.reuteri was from 6,80x10with p <0,001 and the decrease of pH feces was from 5,44 (SB 0,70) to 4,78 (SB0,56) with p <0,001 in the L. reuteri group, otherwise in the Placebo group therewere no significant results in Agachan constipation score, the number of L.reuteriand fecal pH assessed.Conclusion: L.reuteri is more effective than the Placebo group in improving theAgachan constipation score, increasing the number of L. reuteri in the feces anddecreasing the fecal pH in adult with chronic functional constipation."

"LATAR BELAKANG: Keputihan adalah keluhan kewanitaan yang paling sering dijumpai pada pelayanan kesehatan primer, dengan kunjungan berdasarkan data CDC di Amerika Serikat sebanyak 2,7-3,6 juta pasien dengan keluhan keputihan pada tahun 2008. Keputihan abnormal tersering yang disebabkan infeksi adalah Bacterial Vaginosis BV pada 22-50 wanita, Kandidosis VulvoVaginal KVV sebesar 17-39 dan Trikhomoniasis TV sebesar 4-35. Beberapa di antara komplikasi serius yang dapat terjadi pada Bacterial Vaginosis antara lain keguguran, peradangan rongga panggul, persalinan prematur, khorioamnionitis, endometritis postpartum, serta infeksi pascaoperasi ginekologis. Timbulnya keputihan abnormal erat kaitannya dengan perubahan derajat keasaman pH dari keadaan normalnya yaitu 3,5-4,7 yang disebabkan penurunan flora normal laktobasili dan peningkatan mikroba patologis yang menghasilkan keputihan. Diagnosis keputihan dapat ditegakkan berdasarkan pendekatan sindromik, empirik, maupun laboratoris. Probiotik sebagai mikroorganisme hidup yang dapat memberikan keuntungan kesehatan kepada inangnya, dalam hal ini Lactobacillus rhamnosus GR-1 dan Lactobacillus reuteri RC-14 pada beberapa penelitian uji klinis acak tersamar ganda di luar negeri telah terbukti memberikan kesembuhan yang signifikan dibanding terapi standar, baik sebagai terapi utama maupun ajuvan. Penelitian serupa belum pernah dilakukan di Indonesia.TUJUAN: Diketahuinya efektivitas klinis dan dibuktikannya tingginya proporsi kesembuhan dan tingkat kepuasan pascaterapi pasien kombinasi antimikroba-probiotik oral Lactobacillus rhamnosus GR-1 dan Lactobacillus reuteri RC-14 dibanding kombinasi antimikroba-placebo pada pengobatan pasien usia reproduksi dengan keputihan di poliklinik rawat jalan obstetrik dan ginekologi RSCM.METODE: Penelitian ini merupakan penelitian uji klinis acak tersamar ganda dengan jumlah sampel inisial 84 subjek, dan terealisasi 50 subjek dengan populasi target wanita usia reproduksi yang berkunjung dengan keluhan keputihan ke poliklinik rawat jalan RSCM dan RSUD Arifin Achmad Pekanbaru, Riau dan memenuhi kriteria inklusi dan eksklusi, terbagi dalam 25 subjek pada kelompok kontrol dan 25 subjek pada kelompok perlakuan. Data dikumpulkan melalui pemeriksaan klinis dengan pendekatan sindromik, pemberian probiotik yang mengandung masing-masing 2,5x109 CFU Lactobacillus rhamnosus GR-1 dan Lactobacillus reuteri RC-14 sebagai ajuvan terapi antimikroba standar pada kelompok perlakuan dan terapi antimikroba standar ditambah plasebo pada kelompok kontrol, dicatat respon terapi 4 mingggu kemudian menggunakan instrumen formulir pelaporan kasus khusus penelitian dan formulir peniliaian tingkat kepuasan berdasarkan Treatment Satisfaction Questionnaire For Medication TSQM VERSI II . Nilai risiko relatif, dan Uji chi square dilakukan untuk menilai hubungan antar variabel. Analisis interim dengan penilaian conditional power dan uji futilitas dilakukan di tengah penelitian karena jumlah sampel insial tidak tercapai. Penelitan ini sudah lolos kaji etik dan mendapat persetujuan pelaksanaan dari Komite Etik Penelitian Kesehatan FKUI-RSCM pada bulan Maret 2016.HASIL: Sebanyak 50 subjek dapat terkumpul dan dianalisa, terdiri dari 25 subjek perlakuan dan 25 subjek kontrol, dimana sebanyak 14 subjek 56 dari kelompok perlakuan sembuh dan 11 subjek 44 tidak sembuh, serta sebanyak 15 subjek 60 dari kelompok kontrol sembuh dan 10 subjek 40 tidak sembuh, sehingga menghasilkan risiko relatif sebesar 1,1 untuk subjek yang tidak sembuh, dan uji Chi-Square didapatkan nilai p 0,77, IK 95 ; 0,57-2,11 . Pada tingkat kepuasan didapatkan bahwa proporsi tingkat kepuasan tinggi skor 67-100 justru lebih besar pada kelompok plasebo sebesar 52,6 10 subjek dibanding kelompok probiotik sebesar 47,4 9 subjek . Berdasarkan uji statistik didapatkan nilai p sebesar 0,65 ge;0,05 , sehingga tidak ada perbedaan tingkat kepuasan responden pada kelompok perlakuan probiotik maupun kelompok kontrol plasebo . Kekurangan jumlah sampel telah dianalisis dengan kurva conditional power dan uji futilitas untuk mengetahui kemungkinan signifikansi pada jumlah sampel total, dan didapatkan nilai Z = -0.2865, sesuai dengan conditional power antara 0,11-0,13 sehingga indeks futilitas 0,88-0,87, dengan interpretasi bahwa kemungkinan kecil penelitian akan bermakna bila dilanjutkan hingga tercapai sampel total.KESIMPULAN: Tidak ditemukan perbedaan proporsi yang bermakna secara klinis maupun statistik pada tingkat kesembuhan maupun tingkat kepuasan pada pasien usia reproduksi dengan keputihan pada pemberian kombinasi antimikroba-probiotik oral Lactobacillus rhamnosus GR-1 dan Lactobacillus reuteri RC-14 dibanding kombinasi antimikroba-plasebo setelah terapi selama 4 minggu, namun dalam penelitian ini hipotesis awal proporsi kesembuhan kelompok perlakuan probiotik yang lebih tinggi daripada kelompok kontrol plasebo belum bisa ditolak, karena jumlah sampel belum memadai.KATA KUNCI : Keputihan, Bacterial Vaginosis, Kandidosis VulvoVaginal, Trikhomoniasis, Lactobacillus rhamnosus GR-1, Lactobacillus reuteri RC-14, uji klinis acak randomisasi ganda.

---

BACKGROUND Vaginal discharge is one of the most frequent complain encountered in primary health care, as much as 2,7 to 2,6 million visits per year according to data from the CDC in the United States in 2008. The most common abnormal vaginal discharge caused by infection is Bacterial Vaginosis BV in 22 50 of women, vulvovaginal candidosis KVV of 17 39 and Trikhomoniasis TV of 4 35 . Some of the serious complications that may be caused bacterial Vaginosis include miscarriage, pelvic inflammation, premature delivery, chorioamnionitis, postpartum endometritis, as well as gynecological postoperative infection. Abnormal vaginal discharge is closely related to changes in the degree of acidity pH from the normal state which is 3.5 to 4.7 caused a decrease in the normal flora lactobacilli and an increase in microbes that produce pathological vaginal discharge. Diagnosis of vaginal discharge may be established based on syndromic, empirical, and laboratory approach. Probiotics known as living microorganisms that can provide health benefits to the host, in this case Lactobacillus rhamnosus GR 1 and Lactobacillus reuteri RC 14, in several randomized clinical trials, double blinded, have been proven to provide healing significantly compared to standard therapy, either as primary or adjuvant therapy. Such researchs have not been done in Indonesia.OBJECTIVES To acknowledge the clinical effectiveness and prove the high proportion of cure and satisfaction levels of post treatment patients with a combination of antimicrobial probiotic oral Lactobacillus rhamnosus GR 1 and Lactobacillus reuteri RC 14 compared to a combination of antimicrobial placebo in the treatment of patients of reproductive age with vaginal discharge in the clinic outpatient obstetrics and gynecology RSCM.METHODS This study is a randomized, double blind, clinical trial with initial total sample was 84 subjects, and only 50 subjects were able to be analyzed with target population of reproductive age women who visited with complain of vaginal discharge to outpatient clinic at RSCM and Arifin Achmad Pekanbaru, Riau and met the inclusion criteria and exclusion, divided into 25 subjects in the control group and 25 subjects in the treatment group. Data were collected through a clinical examination with syndromic approach, administration of probiotics containing each 2,5x109 CFU Lactobacillus rhamnosus GR 1 and Lactobacillus reuteri RC 14 as an adjuvant standard antimicrobial therapy in the treatment group and placebo plus standard antimicrobial therapy in the control group, therapeutic response was recorded 4 weeks after treatment using the trial spesific case report form and level of satisfaction using a form based on treatment satisfaction Questionnaire For Medication TSQM VERSION II . Relative risk values, and chi square test was performed to assess the relationship between variables. The interim analysis with conditional power assesment and futility testing in the middle of the study was performed due to insufficient sample size. Research has already qualified and approved by Ethics Commitee for Health Researches Faculty of Medicine University of Indonesia RSCM in March 2016.RESULTS A total of 50 subjects has participated and analyzed, consisting of 25 subjects treated and 25 control subjects, with 14 subjects 56 of the treatment group cured and 11 subjects 44 not cured, and as many as 15 subjects 60 cured of the control group and 10 subjects 40 not cured, resulting in a relative risk of 1.1 for subjects that is not cured, and the Chi square test p value 0.77, 95 CI 0.57 to 2 , 11 . On the treatment staisfaction level analysis, it was found that high level of satisfaction score ge 67 unexpectedly higher in the placebo group of 52,6 10 subjetcs compared to probiotic group, of 47,4 9 subjects . Based on statistical test, p value was 0,65 ge 0,05 , equals to no difference in the level of satisfaction of respondents in treatment group probiotic and control group placebo . Lacking number of samples collected 50 subjects have been analyzed with conditional power and futility test curve for possible significancy provided the total number of samples able to be collected, and obtained the value of Z 0.2865, corresponds to conditional power between 0.11 to 0.13 and futility index of 0.87 to 0.88, which may be interpreted as low possibility of reaching statistical significance even if the trial was continued to initially calculated minimum sample.CONCLUSION There was no clinical and statistical difference in the proportion of cure and the level of satisfaction in patients of reproductive age with vaginal discharge in the treatment with combination of antimicrobial oral probiotic Lactobacillus rhamnosus GR 1 and Lactobacillus reuteri RC 14 compared to combination of antimicrobial placebo after treatment for 4 weeks. However in this study, the initial hypothesis of higher proportion of cure at the treatment group probiotic compared to placebo still cannot be excluded, due to insufficient samples collected. KEYWORDS Vaginal discharge, Bacterial Vaginosis. Vulvovaginal candidiasis, Trikhomoniasis, Lactobacillus rhamnosus GR 1, Lactobacillus reuteri RC 14, randomized double blind controlled trial."